Is it time for a moratorium on the use of benzalkonium chloride in eyedrops?

Br J Clin Pharmacol. 2022 Sep;88(9):3947-3949. doi: 10.1111/bcp.15359. Epub 2022 May 8.

Authors

Luca D'andrea¹, Marina Montemagni², Giuseppe Celenza³, Roberto Iorio³, Ciro Costagliola²

Affiliations

¹ Department of Public Health, University of Naples Federico II, Naples, Italy.
² Department of Neurosciences, Reproductive and Dentistry Sciences, University of Naples Federico II, Naples, Italy.
³ Department of Biotechnological and Applied Clinical Sciences, University of Aquila, Aquila, Italy.

No abstract available

Keywords: BAC; OSD; benzalkonium chloride; glaucoma; neuroinflammation; toxicity.

MeSH terms

Antihypertensive Agents / therapeutic use
Benzalkonium Compounds* / adverse effects
Glaucoma* / drug therapy
Humans
Ophthalmic Solutions

Substances

Antihypertensive Agents
Benzalkonium Compounds
Ophthalmic Solutions